Researchers Uncover Link Between Inherited Genes and Rare Blood Cancer. A study by Mayo Clinic researchers found that people with telomere biology disorders often have a high percentage of clonal hematopoiesis, which is associated with an increased risk of developing blood cancer.
The study found that variants in the U2AF1 gene are especially common in people with telomere biology disorders, suggesting that the U2AF1 gene may play a role in developing blood cancer.
The findings are particularly relevant for people with telomere biology disorders, who may be sensitive to certain therapies due to preexisting genomic instability, shortened telomeres, and the potential effect of these therapies on cancer and healthy cells.
Another study, published in the journal Nature Genetics, describes how inherited genetic variants can influence whether a spontaneous mutation occurs in a rare type of blood cancer.
This study helps researchers understand the interplay between cancer-driving genetic mutations and inherited genetic variants in rare blood cancers.
In summary, researchers have found that inherited genes, such as the U2AF1 gene, can play a role in the development of rare blood cancers. These findings can help guide the development of targeted therapies and improve the understanding of the underlying mechanisms of these diseases.
Key Findings of the Study on Inherited Genetic Variants and Rare Blood Cancer
Inherited genetic variants influence the impact of cancer-driving mutations: Specifically, the researchers found that variations in genes affecting blood cell count can determine whether a mutation in the JAK2 gene, known to increase MPN risk, actually leads to the disease.
Natural variation in blood cell count can mimic MPN: Some individuals with inherited predispositions towards higher blood cell counts may exhibit MPN-like features even without the JAK2 mutation, blurring the lines of disease diagnosis.
Combined analysis provides a more complete picture: By analyzing a combination of inherited variants, somatic mutations, and genetic risk scores, the researchers shed light on the complex interplay between genetics and MPN development.
Improved disease prediction potential: Understanding how inherited variations synergize with cancer-driving mutations could allow for more accurate genetic risk assessments and individualized disease prediction.
New avenues for drug development: Identifying specific genetic combinations associated with MPN can pave the way for targeted therapies focusing on those combinations.
Relevance beyond MPN: The findings suggest similar interactions between inherited and acquired genetic factors may play a role in other complex diseases, prompting further research in this direction.
These key findings significantly advance our understanding of MPN and hold promise for better diagnosis, prediction, and potentially new treatment strategies for this rare blood cancer.
Key quotes:
Dr. Jing Guo (first author): “Our study fills the knowledge gaps in how DNA variants, both inherited and somatic, interact to influence complex disease risk.”
Professor Nicole Soranzo (co-senior author): “This confirms a new important contribution of normal variability beyond complex disease, contributing to our understanding of myeloproliferative neoplasms and blood cancer more generally.”
Dr. Jyoti Nangalia (co-senior author): “Our study helps us understand how inherited DNA variation can interact with cancer-causing mutations to determine whether disease occurs. Our hope is that this information can be incorporated into future disease prediction efforts.”
DON’T MISS: Combining ED Drugs and Nitrates in Heart Patients Raises Risks
